FY2029 Earnings Forecast for FULC Issued By HC Wainwright

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for Fulcrum Therapeutics in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.95) per share for the year. HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03).

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Fulcrum Therapeutics presently has an average rating of “Hold” and a consensus price target of $8.63.

Fulcrum Therapeutics Trading Up 6.5 %

Shares of FULC opened at $3.59 on Thursday. The company has a market cap of $193.78 million, a price-to-earnings ratio of -11.58 and a beta of 2.03. Fulcrum Therapeutics has a 1-year low of $2.86 and a 1-year high of $13.70. The company’s fifty day simple moving average is $4.11 and its 200 day simple moving average is $4.57.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at about $38,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after acquiring an additional 4,701 shares during the period. Walleye Capital LLC bought a new stake in shares of Fulcrum Therapeutics in the third quarter valued at about $59,000. Intech Investment Management LLC bought a new stake in shares of Fulcrum Therapeutics in the third quarter valued at about $62,000. Finally, Mariner LLC bought a new stake in shares of Fulcrum Therapeutics in the fourth quarter valued at about $78,000. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.